Clinical trials of HWH217 tablets approved
November 7, 2025
Source: drugdu
58
Humanwell Healthcare(600079) announced on November 6th that its wholly-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" for HWH217 tablets issued by the National Medical Products Administration. HWH217 tablets are a new compound preparation containing known active ingredients, classified as a Class 2.3 chemical drug, and are intended for the treatment of (WHO Group 1) arterial pulmonary hypertension. According to Insight database statistics, there are currently no compound preparations approved for marketing in China for this indication. To date, the cumulative R&D investment in this project is approximately RMB 6 million.
https://finance.eastmoney.com/a/202511063557058041.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
